IL300341A - A pharmaceutical composition of an aquaporin inhibitor and a method for its preparation - Google Patents

A pharmaceutical composition of an aquaporin inhibitor and a method for its preparation

Info

Publication number
IL300341A
IL300341A IL300341A IL30034123A IL300341A IL 300341 A IL300341 A IL 300341A IL 300341 A IL300341 A IL 300341A IL 30034123 A IL30034123 A IL 30034123A IL 300341 A IL300341 A IL 300341A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
bis
trifluoromethyl
phenyl
meglumine
Prior art date
Application number
IL300341A
Other languages
English (en)
Hebrew (he)
Original Assignee
Jiangsu Simcere Pharm Co Ltd
Aeromics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharm Co Ltd, Aeromics Inc filed Critical Jiangsu Simcere Pharm Co Ltd
Publication of IL300341A publication Critical patent/IL300341A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL300341A 2020-08-05 2021-08-04 A pharmaceutical composition of an aquaporin inhibitor and a method for its preparation IL300341A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010779964 2020-08-05
PCT/CN2021/110506 WO2022028459A1 (en) 2020-08-05 2021-08-04 Pharmaceutical composition of aquaporin inhibitor and preparation method thereof

Publications (1)

Publication Number Publication Date
IL300341A true IL300341A (en) 2023-04-01

Family

ID=80120008

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300341A IL300341A (en) 2020-08-05 2021-08-04 A pharmaceutical composition of an aquaporin inhibitor and a method for its preparation

Country Status (12)

Country Link
US (1) US20230293556A1 (cg-RX-API-DMAC10.html)
EP (1) EP4192442A4 (cg-RX-API-DMAC10.html)
JP (1) JP7877294B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230137284A (cg-RX-API-DMAC10.html)
CN (1) CN117337182A (cg-RX-API-DMAC10.html)
AU (1) AU2021323181A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023002129A2 (cg-RX-API-DMAC10.html)
CA (1) CA3187716A1 (cg-RX-API-DMAC10.html)
IL (1) IL300341A (cg-RX-API-DMAC10.html)
MX (1) MX2023001493A (cg-RX-API-DMAC10.html)
TW (1) TW202228714A (cg-RX-API-DMAC10.html)
WO (1) WO2022028459A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
AU2017261828B2 (en) 2016-05-13 2023-04-13 Aeromics, Inc. Crystals
WO2024208207A1 (zh) * 2023-04-03 2024-10-10 拜西欧斯(北京)生物技术有限公司 一种双取代萘化合物及其药物组合物和用途
WO2025075479A1 (ko) * 2023-10-04 2025-04-10 이화여자대학교 산학협력단 아쿠아포린 4 억제제의 심방세동 치료 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7626042B2 (en) * 2002-06-06 2009-12-01 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
US9316633B2 (en) * 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
SG11201604477SA (en) * 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
AU2017261828B2 (en) * 2016-05-13 2023-04-13 Aeromics, Inc. Crystals

Also Published As

Publication number Publication date
EP4192442A1 (en) 2023-06-14
TW202228714A (zh) 2022-08-01
MX2023001493A (es) 2023-06-23
BR112023002129A2 (pt) 2023-04-18
WO2022028459A1 (en) 2022-02-10
US20230293556A1 (en) 2023-09-21
JP7877294B2 (ja) 2026-06-22
JP2023536509A (ja) 2023-08-25
KR20230137284A (ko) 2023-10-04
CN117337182A (zh) 2024-01-02
AU2021323181A1 (en) 2023-03-23
EP4192442A4 (en) 2025-03-19
CA3187716A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CA3187716A1 (en) Pharmaceutical composition of aquaporin inhibitor and preparation method thereof
CA2492467C (en) Injectable depot formulation comprising crystals of iloperidone
EP2676677B1 (en) Highly concentrated anti-cd40 antibody pharmaceutical preparation
EP4066849B1 (en) Daptomycin formulations and uses thereof
US9168238B2 (en) Levothyroxine formulations
KR101351668B1 (ko) 신규 에포프로스테놀 제형 및 이의 제조방법
HU202761B (en) Process for producing stabilized erythropoietin compositions
JP2019142964A (ja) 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法
CA3147328A1 (en) Anti-il-23p19 antibody formulations
JP2018531268A6 (ja) ダントロレンを含む水性組成物
CA3245141A1 (en) LOW-SORPTION GLYBURIDE KIT, FORMULATION AND METHODS
TWI696469B (zh) 調配物
US12629337B2 (en) Daptomycin formulation
KR20070110256A (ko) 유산나트륨 희석제 내에 피페라실린, 타조박탐 및아미노카르복실산을 함유하는 조성물
EP4019033B1 (en) Injectable solution comprising a spirofused tetrapeptide an a ph-regulator for treating kappa opioid receptor-associated conditions
CN107519136B (zh) 一种氯化琥珀胆碱冻干制剂及其制备方法
EP4674418A1 (en) Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method
JP2022531670A (ja) インスリンプレミックスの配合物と製品、それを調製する方法、及びそれを使用する方法
JP2025533237A (ja) 液体ダルババンシン組成物
WO2017198224A1 (zh) 一种瑞马唑仑的药物组合物
US20130131089A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof
HK40081664B (en) Daptomycin formulations and uses thereof
HK40081664A (en) Daptomycin formulations and uses thereof
WO2011137459A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof
CA3268560A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof